These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26291480)
1. A7RC peptide modified paclitaxel liposomes dually target breast cancer. Cao J; Wang R; Gao N; Li M; Tian X; Yang W; Ruan Y; Zhou C; Wang G; Liu X; Tang S; Yu Y; Liu Y; Sun G; Peng H; Wang Q Biomater Sci; 2015 Dec; 3(12):1545-54. PubMed ID: 26291480 [TBL] [Abstract][Full Text] [Related]
2. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment. Jin X; Li M; Yin L; Zhou J; Zhang Z; Lv H Nanomedicine; 2017 Apr; 13(3):1105-1115. PubMed ID: 27845234 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548 [TBL] [Abstract][Full Text] [Related]
4. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818 [TBL] [Abstract][Full Text] [Related]
5. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009 [TBL] [Abstract][Full Text] [Related]
6. PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer. Ju RJ; Cheng L; Xiao Y; Wang X; Li CQ; Peng XM; Li XT J Liposome Res; 2018 Sep; 28(3):236-248. PubMed ID: 28480778 [TBL] [Abstract][Full Text] [Related]
7. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy. Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804 [TBL] [Abstract][Full Text] [Related]
8. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. Xia T; He Q; Shi K; Wang Y; Yu Q; Zhang L; Zhang Q; Gao H; Ma L; Liu J Pharm Dev Technol; 2018 Jan; 23(1):13-21. PubMed ID: 27884084 [TBL] [Abstract][Full Text] [Related]
9. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419 [TBL] [Abstract][Full Text] [Related]
10. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells. Shroff K; Kokkoli E Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611 [TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Meng S; Su B; Li W; Ding Y; Tang L; Zhou W; Song Y; Li H; Zhou C Nanotechnology; 2010 Oct; 21(41):415103. PubMed ID: 20852356 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. Chen X; Plasencia C; Hou Y; Neamati N J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477 [TBL] [Abstract][Full Text] [Related]
13. Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes. Guo Z; Li W; Yuan Y; Zheng K; Tang Y; Ma K; Cui C; Wang L; He B; Zhang Q Drug Deliv; 2018 Nov; 25(1):112-121. PubMed ID: 29260912 [TBL] [Abstract][Full Text] [Related]
14. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. Wang F; Chen L; Zhang R; Chen Z; Zhu L J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829 [TBL] [Abstract][Full Text] [Related]
15. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582 [TBL] [Abstract][Full Text] [Related]
16. Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery. Huang M; Pu Y; Peng Y; Fu Q; Guo L; Wu Y; Zheng Y Bioorg Med Chem Lett; 2020 Jun; 30(12):127151. PubMed ID: 32317211 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608 [TBL] [Abstract][Full Text] [Related]
18. Stabilized Heptapeptide A7R for Enhanced Multifunctional Liposome-Based Tumor-Targeted Drug Delivery. Ying M; Shen Q; Liu Y; Yan Z; Wei X; Zhan C; Gao J; Xie C; Yao B; Lu W ACS Appl Mater Interfaces; 2016 Jun; 8(21):13232-41. PubMed ID: 27195531 [TBL] [Abstract][Full Text] [Related]
19. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332 [TBL] [Abstract][Full Text] [Related]
20. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]